|
|||||
|
|
Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases |
|
| Authors: | Minoru Satoh Monica Vázquez-Del Mercado Edward K. L. Chan |
| Affiliation: | 1. Division of Rheumatology and Clinical Immunology, Department of Medicine, and Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, P.O. Box 100221, Gainesville, FL, 32610-0221, USA 3. Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético Sierra Mojada 950, Planta Baja, CP 44240, Edificio P Ala Oriente, Mexico 4. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico 5. Divisiòn de Medicina Interna, Reumatòloga, Departamento de Reumatologìa, Hospital Civil Juan I, Mechaca, Guadalajara, Jalisco, Mexico 6. Department of Oral Biology, University of Florida, Gainesville, FL, 32610-0424, USA |
| Abstract: | Autoantibody tests have been used extensively in diagnosis and follow-up of patients in rheumatology clinics. Immunofluorescent antinuclear antibody test using HEp-2 cells is still considered the gold standard for screening of autoantibodies, and most of specific autoantibodies are currently tested by ELISA as a next step. Among the many autoantibody specificities described, some have been established as clinically useful diagnostic markers and are included in the classification criteria of diseases. Despite a long history of routine tests and attempts to standardize such assays, there are still limitations and problems that clinicians need to be aware of. Clinicians should be able to use autoantibody tests more efficiently and effectively with a basic knowledge on the significance of and potential problems in autoantibody tests. |
| Keywords: | Antinuclear antibodies Autoantibodies SLE Scleroderma Polymyositis |
| 本文献已被 SpringerLink 等数据库收录！ | |